Detail of "74978-16-8"

Reference

Gastric irritation from Euphyllin, theophylline, ethylenediamine, and Riopan

Gastric irritation from Euphyllin, theophylline, ethylenediamine, and Riopan. Gastric transmural potential differences (GPD). Bruhn, R.; Ganote, D. P.; Luecker, P. W. (Inst. Klin. Pharmakol., Bobenheim D-6719, Fed. Rep. Ger.). 317-34-0 and 107-15-3 are cas registry numbers of chemicals which are used as reagents here. Methods Find. Exp. Clin. Pharmacol., 5(8), 581-3 (German) 1983. CODEN: MFEPDX. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A comparative study of the gastric irritation produced by theophylline (I) [58-55-9], Euphyllin (II) [317-34-0], or ethylenediamine (III) [107-15-3] in healthy volunteers, as measured by changes in gastric transmural potential differences, demonstrated that III was less irritating than II, and II was less irritating than I. Pretreatment with Riopan [74978-16-8] decreased the gastric irritability of I. .

Bioavailability studies with etodolac in dogs and man

Bioavailability studies with etodolac in dogs and man. Kraml, M.; Cosyns, L.; Hicks, D. R.In this study， 54182-58-0 and 74978-16-8 are also used.; Simon, J.; Mullane, J. F.; Dvornik, D. (Ayerst Res. Lab., Montreal, PQ H4R 1J6, Can.). Biopharm. Drug Dispos., 5(1), 63-74 (English) 1984. CODEN: BDDID8. ISSN: 0142-2782. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The effects of formulation, particle size, coadministration of food, antacids, or antiulcer agents on the bioavailability of etodolac (Ultradol)(I) [41340-25-4], a novel nonsteroidal anti-inflammatory agent, were evaluated in dogs and humans. The effects of dosage regimen and/or repetitive dosing on bioavailability were also detd. In humans, capsule and tablet dosage forms contg. micronized I had a bioavailability (area under the concn.-time curve) (AUC) equal to that of the ref. I soln. I from tablets and capsules was rapidly absorbed since only minor decreases in the max. concn. (Cmax) and increases in the time to reach the max. concn. were obsd. compared to the I soln. In a comparison of regular and micronized I dosage forms, both in dogs and man, similar findings, i.e. no change in AUC but small parallel changes in Cmax and tmax, were obsd. Administration of I with food had no effect on the I bioavailability in dogs but tended to cause a delay in its absorption. The coadministration of an antacid, magaldrate [74978-16-8], or the antiulcer agent, sucralfate [54182-58-0], had no effect on the bioavailability of I in dogs, although with the latter, a significant redn. in Cmax was noted. In humans, I may be administered as a single bolus dose or in divided doses without any loss in bioavailability. With either regimen, on repeat administration for 7 days, no I accumulation was noted. .